Elemer Piros
Stock Analyst at LUCID CAPITAL MARKETS
(2.86)
# 1,866
Out of 4,964 analysts
108
Total ratings
40.2%
Success rate
9.27%
Average return
Main Sectors:
Stocks Rated by Elemer Piros
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BTAI BioXcel Therapeutics | Reiterates: Buy | $66 | $4.10 | +1,509.76% | 2 | Jul 15, 2025 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.62 | +1,834.86% | 1 | Dec 12, 2024 | |
| THAR Tharimmune | Initiates: Buy | $17 | $6.05 | +180.99% | 1 | Dec 6, 2024 | |
| QNCX Quince Therapeutics | Initiates: Buy | $11 | $1.54 | +614.29% | 1 | Oct 29, 2024 | |
| MNPR Monopar Therapeutics | Initiates: Buy | $50 | $36.06 | +38.66% | 6 | Oct 11, 2024 | |
| MIRA MIRA Pharmaceuticals | Initiates: Buy | $17 | $1.40 | +1,114.29% | 1 | Sep 30, 2024 | |
| ATHA Athira Pharma | Initiates: Buy | $22 | $0.40 | +5,462.58% | 1 | Aug 19, 2024 | |
| SAVA Cassava Sciences | Reiterates: Buy | $107 | $2.38 | +4,395.80% | 1 | Aug 8, 2024 | |
| CGTX Cognition Therapeutics | Reiterates: Buy | $14 | $2.48 | +464.52% | 1 | Jul 2, 2024 | |
| ANVS Annovis Bio | Reiterates: Buy | $67 | $2.32 | +2,787.93% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $3.81 | +1,028.61% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $6.65 | +170.68% | 7 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7.5 | $1.21 | +519.83% | 3 | Sep 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $4.65 | +222.58% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $21 | $9.78 | +114.72% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $4.81 | +690.02% | 9 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $0.84 | +4,655.68% | 2 | Jul 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $4.20 | +1,090.48% | 5 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $114 | $7.64 | +1,392.15% | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $200 | $5.41 | +3,596.86% | 6 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $3.41 | +574.49% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $33 | $13.84 | +138.44% | 3 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $40 | $28.05 | +42.60% | 7 | Apr 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $1.83 | +1,922.96% | 1 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $32 | $5.87 | +445.14% | 2 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $77 | $17.30 | +345.09% | 2 | Dec 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $1.94 | +3,508.25% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.90 | - | 5 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $50 | $22.34 | +123.81% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $33 | $5.86 | +463.14% | 2 | Oct 22, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $10.27 | - | 3 | Jul 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $4.23 | +514.66% | 3 | May 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $150.76 | -81.43% | 1 | Sep 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $525 → $850 | $6.88 | +12,254.65% | 1 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $21 | $12.52 | +67.73% | 2 | Jul 12, 2017 |
BioXcel Therapeutics
Jul 15, 2025
Reiterates: Buy
Price Target: $66
Current: $4.10
Upside: +1,509.76%
FibroBiologics
Dec 12, 2024
Initiates: Buy
Price Target: $12
Current: $0.62
Upside: +1,834.86%
Tharimmune
Dec 6, 2024
Initiates: Buy
Price Target: $17
Current: $6.05
Upside: +180.99%
Quince Therapeutics
Oct 29, 2024
Initiates: Buy
Price Target: $11
Current: $1.54
Upside: +614.29%
Monopar Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $50
Current: $36.06
Upside: +38.66%
MIRA Pharmaceuticals
Sep 30, 2024
Initiates: Buy
Price Target: $17
Current: $1.40
Upside: +1,114.29%
Athira Pharma
Aug 19, 2024
Initiates: Buy
Price Target: $22
Current: $0.40
Upside: +5,462.58%
Cassava Sciences
Aug 8, 2024
Reiterates: Buy
Price Target: $107
Current: $2.38
Upside: +4,395.80%
Cognition Therapeutics
Jul 2, 2024
Reiterates: Buy
Price Target: $14
Current: $2.48
Upside: +464.52%
Annovis Bio
Jul 2, 2024
Reiterates: Buy
Price Target: $67
Current: $2.32
Upside: +2,787.93%
Jun 21, 2024
Initiates: Buy
Price Target: $43
Current: $3.81
Upside: +1,028.61%
Jun 13, 2024
Initiates: Buy
Price Target: $18
Current: $6.65
Upside: +170.68%
Sep 14, 2023
Maintains: Buy
Price Target: $12 → $7.5
Current: $1.21
Upside: +519.83%
Aug 9, 2023
Reiterates: Buy
Price Target: $15
Current: $4.65
Upside: +222.58%
Aug 4, 2023
Reiterates: Buy
Price Target: $21
Current: $9.78
Upside: +114.72%
Aug 3, 2023
Reiterates: Buy
Price Target: $38
Current: $4.81
Upside: +690.02%
Jul 10, 2023
Reiterates: Buy
Price Target: $40
Current: $0.84
Upside: +4,655.68%
Jun 30, 2023
Reiterates: Buy
Price Target: $50
Current: $4.20
Upside: +1,090.48%
Jun 20, 2023
Reiterates: Buy
Price Target: $114
Current: $7.64
Upside: +1,392.15%
Jun 20, 2023
Maintains: Buy
Price Target: $260 → $200
Current: $5.41
Upside: +3,596.86%
May 16, 2023
Reiterates: Buy
Price Target: $23
Current: $3.41
Upside: +574.49%
Mar 2, 2023
Reiterates: Buy
Price Target: $33
Current: $13.84
Upside: +138.44%
Apr 14, 2022
Downgrades: Sell
Price Target: $40
Current: $28.05
Upside: +42.60%
Dec 1, 2021
Initiates: Buy
Price Target: $37
Current: $1.83
Upside: +1,922.96%
Jun 30, 2021
Maintains: Buy
Price Target: $38 → $32
Current: $5.87
Upside: +445.14%
Dec 23, 2020
Downgrades: Sell
Price Target: $77
Current: $17.30
Upside: +345.09%
Oct 12, 2020
Initiates: Buy
Price Target: $70
Current: $1.94
Upside: +3,508.25%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $9.90
Upside: -
Nov 19, 2019
Maintains: Neutral
Price Target: $24 → $50
Current: $22.34
Upside: +123.81%
Oct 22, 2019
Assumes: Overweight
Price Target: $33
Current: $5.86
Upside: +463.14%
Jul 11, 2019
Upgrades: Overweight
Price Target: n/a
Current: $10.27
Upside: -
May 6, 2019
Initiates: Overweight
Price Target: $26
Current: $4.23
Upside: +514.66%
Sep 11, 2018
Initiates: Overweight
Price Target: $28
Current: $150.76
Upside: -81.43%
Oct 12, 2017
Maintains: Overweight
Price Target: $525 → $850
Current: $6.88
Upside: +12,254.65%
Jul 12, 2017
Maintains: Overweight
Price Target: $35 → $21
Current: $12.52
Upside: +67.73%